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2012;5:111–21.REPLY: Effectiveness of Antitachycardia
Pacing for Recurrent Ventricular Tachycardia
in ARVCDrs. Santangeli and Marchlinski have asked that we
clarify and expand on the treatment of arrhythmias
described in our recent report (1). We appreciate
this opportunity to respond.
Of the 108 patients with implantable cardioverter-
deﬁbrillators (ICDs) included in the registry, 48 pa-
tients had 502 sustained and treated episodes of
ventricular arrhythmia. Forty-three patients under-
went antitachycardia pacing (ATP) attempts for
ventricular tachycardia (VT); the other 5 patients
received only shock therapy. The number of ATP
attempts per patient ranged from 1 to 96; 28 patients
had #10 attempts. Forty-two of the 43 patients had
at least 1 successful ATP treatment for VT. Twenty-
seven patients had only successful ATP treatment.
Only 3 patients had more failed ATP attempts than
successful ATP attempts. Thus, programming the
ICDs to ﬁrst deliver ATP resulted in the avoidance of
shock treatment in a signiﬁcant number of patients,
and there were no fatalities. We stand by our
conclusion that “all ICDs should be programmed for
ATP, even for rapid VT” (1). However, ATP was not
always successful, because 16 patients had at least
1 ATP failure that resulted in an ICD shock. In total,
30 patients had 89 ICD shocks (average: 3; range: 1
to 9). We are not aware of any episodes of
arrhythmia that were excluded; all episodes of
arrhythmias reported to us were included in our
analysis. It is possible that there were episodes of
ICD shocks and ATP that were not reported to us
and thus could not be included in our analysis.
Drs. Santangeli and Marchlinski also requested
details on ICD programming and management of
recurrent VT during follow-up. In this registry, ICD
programming was left to the discretion of the
physician performing implantation and follow-up.
We do not have details regarding the lower rate
programmed for VT or the duration of VT for
which the ICD would have attempted treatment.
Fifty-three of the 108 patients with an ICD were
treated with antiarrhythmic drugs, and the detailshave been reported in another paper (2). Brieﬂy, in
this patient population, 58 patients who were
treated with beta-blockers did not have an increased
or decreased risk of arrhythmia. Treatment with
sotalol (n ¼ 38) was associated with an increased
risk of ventricular arrhythmias, and the 10 patients
treated with amiodarone had a signiﬁcantly lower
risk of ventricular arrhythmias. Fifteen patients
underwentablation.
Drs. Santangeli and Marchlinski commented on the
high efﬁcacy of the combination of endo-epicardial
catheter ablation. We agree that the reported data
show 1-year efﬁcacy of approximately 70%. We also
agree that the best treatment strategy regarding
recurrent VT remains to be determined, especially
with regard to ablation. In the population studied,
there was no attempt to prevent or promote ablation.
Indeed, 15 of the patients underwent ablation during
the study. However, we do not have data on whether
the attempts at ablation were endo-epicardial or on
the efﬁcacy of ablation in these patients.*Mark S. Link, MD
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and Hypertrophic
Cardiomyopathy
Obiter Dictum or More?We read with interest the state-of-the-art paper
on the present and future of hypertrophic cardio-
myopathy (HCM) by Maron et al. (1), well-known
